Results 61 to 70 of about 3,967 (153)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

open access: yesInfection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA   +4 more
doaj  

Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review [PDF]

open access: yes, 2023
Introduction: Not enough data exist to inform the optimal duration and type of antimicrobial therapy against GN infections in critically ill patients. Methods: Narrative review based on a literature search through PubMed and Cochrane using the following ...
Agarossi A.   +8 more
core   +1 more source

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

open access: yesClinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen   +3 more
wiley   +1 more source

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections [PDF]

open access: yes, 2020
Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections.
Allen, David   +14 more
core   +1 more source

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies [PDF]

open access: yes, 2022
Carbapenem resistance; Gram-negative; CefiderocolResistència als carbapenems; Gram-negatius; CefiderocolResistencia a carbapenémicos; Gram-negativo; CefiderocolIntroduction Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the ...
Bassetti, Matteo   +7 more
core   +1 more source

A review of antibiotic safety in pregnancy—2025 update

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen   +8 more
wiley   +1 more source

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside

open access: yesAntibiotics, 2021
Gram-negative bacilli septic thrombosis (GNB-ST) represents a subtle and often misleading condition, potentially fatal if not recognized early and requiring prolonged antimicrobial therapy and anticoagulation.
Alessandra Oliva   +9 more
doaj   +1 more source

Epidemiology, Treatment, and Outcomes of Gram‐Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients

open access: yesClinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg   +11 more
wiley   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

open access: yesJournal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm   +16 more
doaj   +1 more source

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

open access: yesEFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards)   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy